BACKGROUND: Viral infections can cause significant morbidity in cystic fibrosis (CF). The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic could therefore have a serious impact on the health of people with CF (pwCF). METHODS: We used the 38-country European Cystic Fibrosis Society Patient Registry (ECFSPR) to collect case data about pwCF and SARS-CoV-2 infection. RESULTS: Up to 30 June 2020, 16 countries reported 130 SARS-CoV-2 cases in people with CF, yielding an incidence of 2.70/1000 pwCF. Incidence was higher in lung-transplanted patients (n=23) versus non-transplanted patients (n=107) (8.43 versus 2.36 cases/1000). Incidence was higher in pwCF versus the age-matched general population in the age groups <15, 15-24, and 25-49 years (p<0.001), with similar trends for pwCF with and without lung transplant. Compared to the general population, pwCF (regardless of transplantation status) had significantly higher rates of admission to hospital for all age groups with available data, and higher rates of intensive care, although not statistically significant. Most pwCF recovered (96.2%), however 5 died, of whom 3 were lung transplant recipients. The case fatality rate for pwCF (3.85%, 95% CI: 1.26-8.75) was non-significantly lower than that of the general population (7.46%; p=0.133). CONCLUSIONS: SARS-CoV-2 infection can result in severe illness and death for pwCF, even for younger patients and especially for lung transplant recipients. PwCF should continue to shield from infection and should be prioritized for vaccination.
- Naehrlich, L.
- Orenti, A.
- Dunlevy, F.
- Kasmi, I.
- Harutyunyan, S.
- Pfleger, A.
- Keegan, S.
- Daneau, G.
- Petrova, G.
- Tješić-Drinković, D.
- Yiallouros, P.
- Bilkova, A.
- Olesen, H. V.
- Burgel, P. R.
- Parulava, T.
- Diamantea, F.
- Párniczky, A.
- McKone, E. F.
- Mei-Zahav, M.
- Salvatore, M.
- Colombo, C.
- Aleksejeva, E.
- Malakauskas, K.
- Schlesser, M.
- Fustik, S.
- Turcu, O.
- Zomer-van Ommen, D.
- Wathne, A. S.
- Woźniacki, Ł
- Pereira, L.
- Pop, L.
- Kashirskaya, N.
- Rodić, M.
- Kayserova, H.
- Krivecs, U.
- Mondejar-Lopez, P.
- de Monestrol, I.
- Dogru, D.
- Makukh, H.
- Cosgriff, R.
- van Koningsbruggen-Rietschel, S.
- Jung, A.
Keywords
- Covid-19
- Cystic fibrosis
- Epidemiology
- Europe
- Incidence
- SARS-CoV-2
- institutional fees for site participation in clinical trials from Vertex
- Pharmaceuticals and Boehringer Ingelheim
- Dr. Orenti has nothing to disclose
- Dr.
- Dunlevy reports institutional grants from Chiesi, during the conduct of the study
- Dr. Kasmi has nothing to disclose
- Dr. Harutyunyan has nothing to disclose
- Dr.
- Pfleger has nothing to disclose
- Dr. Bobrovnichy has nothing to disclose
- Dr. Keegan
- has nothing to disclose
- Dr. Daneau has nothing to disclose
- Dr. Petrova has nothing
- to disclose
- Dr. Bambir has nothing to disclose
- Dr. Vukić Dugac has nothing to
- disclose
- Dr. Tješić-Drinković has nothing to disclose
- Dr. Yiallouros has nothing
- to disclose
- Dr. Drevinek reports personal fees from Vertex Pharmaceuticals, outside
- the submitted work
- Prof. Milan Macek reports grants from Vertex Pharmaceuticals,
- outside the submitted workr r
- Mrs. Bilkova has nothing to disclose
- Dr. Olesen has
- nothing to disclose
- Dr. Burgel reports personal fees from Astra-Zeneca, personal
- fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from GSK,
- personal fees from Insmed, personal fees from Novartis, personal fees from Pfizer,
- grants and personal fees from Vertex, personal fees from Zambon, outside the
- submitted work
- Dr. Corvol has nothing to disclose
- Ms. Lemmonier has nothing to
- disclose
- Dr. Parulava has nothing to disclose
- Dr. Hatziagorou has nothing to
- disclose
- Dr. Diamantea has nothing to disclose
- Dr. Párniczky has nothing to
- disclose
- G. Fletcher has nothing to disclose
- Prof. McKone reports travel support
- from A Menarini, speaker fees from Roche Pharmaceuticals, consultancy fees from
- Insmed, consultancy fees from Janssen Pharmaceuticals, grants to institution and
- consultancy fees from Vertex, outside the submitted work
- Dr. Mei-Zahav has nothing
- to disclose
- Dr. Padoan has nothing to disclose
- Dr. Salvatore has nothing to
- disclose
- Dr. Colombo has nothing to disclose
- Dr. Aleksejeva has nothing to
- disclose
- Dr. Malakauskas has nothing to disclose
- Dr. Schlesser has nothing to
- disclose
- Dr. Fustik has nothing to disclose
- Dr. Turcu has nothing to disclose
- V.
- Gulmans has nothing to disclose
- D. Zomer-van Ommen has nothing to disclose
- Dr.
- Wathne has nothing to disclose
- Dr. Bakkeheim has nothing to disclose
- Dr. Wozniacki
- has nothing to disclose
- Dr. Pereira has nothing to disclose
- Dr. Pop has nothing to
- disclose
- Dr. Kondratyeva has nothing to disclose
- Dr. Amelina has nothing to
- disclose
- Dr. Zhekaite has nothing to disclose
- Dr. O. Simonova has nothing to
- disclose
- Dr. Kashirskaya has nothing to disclose
- Dr. Rodic has nothing to
- disclose
- Dr. Kayserova has nothing to disclose
- Dr. Krivec has nothing to disclose
- Dr. Mondejar-Lopez has nothing to disclose
- Dr. Pastor-Vivero has nothing to
- disclose
- Dr. de Monestrol reports grants from Vertex, outside the submitted work
- Dr. Lindblad has nothing to disclose
- Dr. Dogru has nothing to disclose
- Dr.
- Gokdemir has nothing to disclose
- Dr. Pekcan has nothing to disclose
- Dr. Makukh has
- nothing to disclose
- Dr. Brownlee has nothing to disclose
- Ms. Cosgriff has nothing
- to disclose
- Mr. McClenaghan has nothing to disclose
- Dr. Carr reports personal fees
- from Chiesi Pharmaceuticals, personal fees and non-financial support from Vertex,
- personal fees from Zambon, personal fees from Insmed, outside the submitted work
- Dr. Lammertyn has nothing to disclose
- Dr. Zolin has nothing to disclose
- Ms.. Fox
- reports grants from ECFS, during the conduct of the study
- Mr Krasnyk has nothing to
- disclose
- Mrs. Van Rens has nothing to disclose
- Dr. van Koningsbruggen-Rietschel
- reports grants and personal fees from Algipharma (HORIZON2020), personal fees from
- Deutsches Zentrum für Infektionsforschung, personal fees from Antabio, personal fees
- from Proteostasis, personal fees from Roche, personal fees from Vertex, outside the
- submitted work
- Dr. Jung reports grants from Chiesi Pharmaceuticals, during the
- conduct of the study.
